Taysha Gene Therapies Income from Continuous Operations 2020-2024 | TSHA
Taysha Gene Therapies income from continuous operations from 2020 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Taysha Gene Therapies Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$-112 |
| 2022 |
$-166 |
| 2021 |
$-175 |
| 2020 |
$-60 |
| 2019 |
$ |
Taysha Gene Therapies Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$-21 |
| 2024-03-31 |
$-24 |
| 2023-12-31 |
$48 |
| 2023-09-30 |
$-117 |
| 2023-06-30 |
$-25 |
| 2023-03-31 |
$-18 |
| 2022-12-31 |
$-55 |
| 2022-09-30 |
$-27 |
| 2022-06-30 |
$-34 |
| 2022-03-31 |
$-50 |
| 2021-12-31 |
$-50 |
| 2021-09-30 |
$-51 |
| 2021-06-30 |
$-41 |
| 2021-03-31 |
$-32 |
| 2020-12-31 |
$-18 |
| 2020-09-30 |
$-15 |
| 2020-06-30 |
$-21 |
| 2020-03-31 |
$-5 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.490B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
